在 FRESCO 试验中接受呋喹替尼治疗的转移性结直肠癌患者的质量调整生存。
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
机构信息
Department of Medical Oncology, Cancer Center of Jinling Hospital, Nanjing, 210029, China.
Tongji University East Hospital, Department of Medical Oncology, Shanghai, 200120, China.
出版信息
Future Oncol. 2021 May;17(15):1923-1931. doi: 10.2217/fon-2020-1215. Epub 2021 Feb 10.
To assess whether the survival benefit of fruquintinib is quality-adjusted. Data of 416 metastatic colorectal cancer patients from the Phase III FRESCO trial were used. The Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) analysis assessed the quality-adjusted survival benefit of fruquintinib versus placebo, accounting for freedom from symptomatic disease and from severe side effects of treatment. Fruquintinib significantly improved patients' Q-TWiST (difference: 2.23 [1.41, 3.04] months) versus placebo. The Q-TWiST gain was 28.3% in the base case and ranged from 16.7 to 39.9% in the threshold analysis, favoring fruquintinib. The Q-TWiST benefit was observed in fruquintinib-treated patients regardless of prior targeted therapy. Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo as a third-line treatment for metastatic colorectal cancer patients.
评估呋喹替尼的生存获益是否经过质量调整。使用来自 III 期 FRESCO 试验的 416 名转移性结直肠癌患者的数据。质量调整无病生存时间和毒性时间（Q-TWiST）分析评估了呋喹替尼与安慰剂相比的生存质量调整获益，同时考虑了无症状疾病和治疗严重副作用的情况。与安慰剂相比，呋喹替尼显著改善了患者的 Q-TWiST（差异：2.23 [1.41, 3.04] 个月）。在基础情况下，Q-TWiST 获益为 28.3%，在阈值分析中范围为 16.7%至 39.9%，均有利于呋喹替尼。无论患者之前是否接受过靶向治疗，接受呋喹替尼治疗的患者均观察到 Q-TWiST 获益。作为转移性结直肠癌三线治疗药物，呋喹替尼与安慰剂相比提供了具有临床意义的生存质量调整获益。
Zotero 插件